Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

FDA clears pioglitazone for type II diabetes

July 19, 1999

SB identifies nonprodrug integrin antagonist with excellent oral bioavailability

July 16, 1999

Novel antidiabetic pyridines and pyrimidines described by Novo Nordisk

July 16, 1999

New, physiologically balanced plasma volume expander now available in the U.S.

July 15, 1999

International patent covers Kowa's new ACAT inhibitors

July 15, 1999

Positive results announced for D-chiro-inositol in type II diabetes trial

July 15, 1999

Preclinical trials demonstrate neuroprotective activity of Vertex's neurophilin compounds

July 15, 1999

New integrin receptor antagonists in the Merck pipeline

July 14, 1999

Insulin secretion enhancers under study at Lilly for use in conditions of impaired glucose disposal

July 14, 1999

Vivus terminates agreement with Bio-Medic Institute

July 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...